Home  »  Finance   »  Analysts Predict An VYNE Therapeutics Inc. (NASDAQ...

Analysts Predict An VYNE Therapeutics Inc. (NASDAQ: VYNE) Spike?

VYNE Therapeutics Inc. (NASDAQ:VYNE) shares, rose in value on Friday, 05/13/22, with the stock price up by 7.25% to the previous day’s close as strong demand from buyers drove the stock to $0.40.

Actively observing the price movement in the last trading, the stock closed the session at $0.37, falling within a range of $0.3676 and $0.4199. Referring to stock’s 52-week performance, its high was $4.24, and the low was $0.34. On the whole, VYNE has fluctuated by -29.55% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of VYNE Therapeutics Inc. currently standing at about $22.87 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 02, 2022 – Mar 07, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.24, which is expected to increase to -$0.15 for fiscal year -$1.36 and then to about -$0.78 by fiscal year 2022. Data indicates that the EPS growth is expected to be 82.70% in 2022, while the next year’s EPS growth is forecast to be 42.60%.

Analysts have estimated the company’s revenue for the quarter at $4.12 million, with a low estimate of $3.9 million and a high estimate of $4.4 million. According to the average forecast, sales growth in current quarter could jump down -3.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $16.57 million, representing a decrease of -21.10% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VYNE’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VYNE currently trading nearly -8.56% and -27.82% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.68, while the 7-day volatility ratio is showing 13.44% which for the 30-day chart, stands at 10.76%. Furthermore, VYNE Therapeutics Inc. (VYNE)’s beta value is 1.09, and its average true range (ATR) is 0.05.

Data on historical trading for VYNE Therapeutics Inc. (NASDAQ:VYNE) indicates that the trading volumes over the past 3 months, they’ve averaged 706.13K. According to company’s latest data on outstanding shares, there are 53.55 million shares outstanding.

Nearly 3.10% of VYNE Therapeutics Inc.’s shares belong to company insiders and institutional investors own 25.40% of the company’s shares. The stock has fallen by -60.97% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VYNE stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam